Mankind Pharma Limited signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialize the acidity medication Vonoprazan in India. The agreement permits Mankind Pharma to market the novel drug for treating Gastroesophageal Reflux Disease (GERD) under its own trademark.
GERD is a chronic condition characterized by stomach acid or bile irritating the lining of the esophagus, leading to frequent acid reflux and heartburn.
Vonoprazan, known by brand names such as Voquezna, is a potassium-competitive acid blocker (P-CAB) medication. It is used in the form of fumarate to treat various conditions, including gastric ulcers, erosive esophagitis, duodenal ulcers, peptic ulcers, gastroesophageal reflux, reflux esophagitis, and for the eradication of Helicobacter pylori.
As reported by business-standard.com, Mankind Pharma is involved in the healthcare sector, offering products across multiple categories such as antibiotics, gastrointestinal, cardiovascular, dermatological, and erectile dysfunction medications.
